4//SEC Filing
Campbell Bradley L 4
Accession 0001193125-25-301018
CIK 0001178879other
Filed
Nov 25, 7:00 PM ET
Accepted
Nov 26, 9:17 PM ET
Size
8.7 KB
Accession
0001193125-25-301018
Insider Transaction Report
Form 4
Campbell Bradley L
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2025-11-24$9.03/sh+14,587$131,721→ 1,151,869 total - Sale
Common Stock
2025-11-24$10.04/sh−14,587$146,522→ 1,137,282 total - Exercise/Conversion
Stock Options (right to buy)
2025-11-24−14,587→ 85,013 totalExercise: $9.03Exp: 2026-01-04→ Common Stock (14,587 underlying)
Footnotes (2)
- [F1]This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.00 to $10.17 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]All of the options were fully vested and exercisable as of the transaction date.
Documents
Issuer
AMICUS THERAPEUTICS, INC.
CIK 0001178879
Entity typeother
Related Parties
1- filerCIK 0001400971
Filing Metadata
- Form type
- 4
- Filed
- Nov 25, 7:00 PM ET
- Accepted
- Nov 26, 9:17 PM ET
- Size
- 8.7 KB